medigraphic.com
ISSN 0188-9796 (Print)

2011, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2011; 19 (3)

DPP-4 inhibitors in the treatment of hyperglycemia induced by chronic use of steroids

Taméz-Pérez HE, Dolores-Gómez M, Tamez AL, Quintanilla DL, Cisneros-Franco JM, Hernández-Coria MI, González-González JG

Language: Spanish
References: 11
Page: 102-105
PDF size: 72.37 Kb.


ABSTRACT

Background: One of the most common and feared side effects of glucocorticoid treatment is the induction of hyperglycemia. Yet, there are no specific clinical guidelines in regards to its management. Objective: To evaluate the efficacy of sitagliptine, a DPP-4 inhibitor in a group of patients with steroid-induced hyperglycemia (SIH). Methods: Sitagliptine, 100 mg per day was administered to 19 patients with SIH. Glucorticoid therapy had been indicated for several rheumatological and neurological conditions. Efficacy of the intervention was established by means of measuring fasting blood glucose and glycosilated hemoglobine (HbA1c) before and after 6 months of treatment with the DPP-4 inhibitor. Results: Nineteen patients were included in the study; the mean age was 42 ± 7 years, and the mean body mass index 31 ± 1.37 kg/m2. Prior to the initiation of treatment the mean fasting blood glucose and HbA1c levels were 184 ± 16 mg/dL and 8.1 ± 0.84%, respectively; these values decreased significantly at the end of therapy to 124 ± 13 mg/dL and 6.1 ± 0.18%, respectively (p ≤ 0.001). Conclusions: DPP-4 inhibitors in general and sagliptine in particular, constitute an effective and safe treatment of SIH.


REFERENCES

  1. Saigi I, Pérez A. Manejo de la hiperglucemia inducida por esteroides. Rev Clin Esp 2010; 210: 397-403.

  2. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, Ostenson AG, Gustafsson JA, Efendic S, Okret A. Pancreatic b cells are important targets for the diabetogenic effects of glucocrticoids. J Clin Invest 1997; 100: 2094-2098.

  3. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15: 469-474.

  4. Girolamo GD, Tamez-Peña AL, Taméz-Pérez HE. Inhibidores de la dipeptidil peptidasa-4: farmacodinámica, farmacocinética y seguridad. Med Int Méx 2008; 24: 142-147.

  5. Bayon C, Barriga MA, Litwak L. Incretinas, incretinomiméticos, inhibidores de DPP IV-1era parte. RAEM 2010; 47: 36-51.

  6. Position Statement: American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes Care 2010; 33: S11-S61.

  7. Davidson JA. Advances in therapy for type 2 diabetes; GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009; 76: S28-S38.

  8. Guillford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006; 29: 2728-2729.

  9. Qui A, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 2007; 292: E654-E667.

  10. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 2010; 95: 3309-3317.

  11. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009; 373: 1798-1807.




2020     |     www.medigraphic.com